The advent of biosimilars for the treatment of diabetes: current status and future directions.
about
Biopharmaceuticals from microorganisms: from production to purificationClinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine.Biosimilar insulins: Informed choice for South Asia.How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
P2860
The advent of biosimilars for the treatment of diabetes: current status and future directions.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The advent of biosimilars for ...... status and future directions.
@en
type
label
The advent of biosimilars for ...... status and future directions.
@en
prefLabel
The advent of biosimilars for ...... status and future directions.
@en
P2093
P2860
P1433
P1476
The advent of biosimilars for ...... status and future directions.
@en
P2093
Achille P Caputi
Gianluca Trifirò
Giovanni Polimeni
Ylenia Ingrasciotta
P2860
P2888
P304
P356
10.1007/S00592-015-0771-7
P577
2015-05-20T00:00:00Z
P5875
P6179
1051253289